In addition, organizations like the World Health Organization (WHO), Ministries of Health and other partners should focus on strategies that enhance universal access to NCD medicines such as providing free insulin to T1DM patients who are dependent on exogenous insulin for normal metabolism. This evidence concerns the gene INS and type 1 diabetes mellitus.